| Data Sharing Statement |  |  |
| :---: | :---: | :---: |
| Article Info | http://dx.doi.org/10.21037/apm-20-385 |  |
| Item | Question | Authors' Response (place "-" if not applicable) |
| 1 | Would you like to share data collected for your study to others? | Yes |
| 2 | If not, would you like to share the reason for your decision? | N/A |
| 3 | What data in particular will be shared? | Patient demographic data, staging data, failure data, treatment time data, IGRT data, palliation data, toxicity data, dosimetric data. |
| 4 | Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | N/A |
| 5 | When will data availability begin? | From the publication date. |
| 6 | When will data availability end? | Two years within the publication date. |
| 7 | To whom will you share the data? | Radiation Oncologists and Medical Physicists who are interested in studies of Halcyon radiotherapy. |
| 8 | For what type of analysis or purpose? | For analysis to evaluate the safety and efficacy of Halcyon radiotherapy in patients with malignant pleural mesothelioma. |
| 9 | How or where can the data/documents be obtained? | Emails could be sent to the address below to request the shared data: <br> Andrew.Barsky@uphs.upenn.edu |
| 10 | Any other restrictions? | We may balance the potential benefits and risks for each request and then provide the data that could be shared. |

